Ratings Theracryf Plc

Equities

EVG

GB00BSVYN304

Market Closed - London S.E. Other stock markets 11:35:00 2024-05-02 am EDT			5-day change	1st Jan Change
0.75 ^GBX	0.00%		-6.25%	-53.12%

Apr. 26	Evgen Pharma plc will Change its Ticker to TCF from EVG	CI
Apr. 26	Evgen Pharma plc will Change its Name to TheraCryf plc	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The company's enterprise value to sales, at 2.1 times its current sales, is high.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
THERACRYF PLC	-55.00%	4M	-
VERTEX PHARMACEUTICALS INCORPORATED	-1.50%	104B	B+
REGENERON PHARMACEUTICALS, INC.	+4.59%	97.47B	B+
ARGENX SE	+5.68%	22.25B	B
BIONTECH SE	-13.13%	21.68B	B+
GENMAB A/S	-9.61%	18.2B	A-
WUXI APPTEC CO., LTD.	-39.98%	17.02B	A-
BEIGENE, LTD.	-11.30%	16.36B	B
NEUROCRINE BIOSCIENCES, INC.	+7.54%	14.39B	C+
SAREPTA THERAPEUTICS, INC.	+40.53%	12.37B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes